Stock Movers: Intel, Viking Therapeutics, Home Depot (Podcast)

Intel (INTC) shares rallied following SoftBank's $2 billion stock purchase and the potential for a 10% US government equity stake, converting CHIPS Act grants into up to $10 billion in capital, signaling significant financial backing for the chipmaker. Conversely, Viking Therapeutics (VKTX) plummeted after its experimental oral obesity pill's mid-stage trial reported a 28% patient dropout rate due to side effects, dampening its competitive prospects against leading injectable treatments. Home Depot (HD) shares advanced as its second-quarter comparable sales returned to growth at 1%, indicating a potential stabilization and recovery in the home improvement sector.

Analysis

Intel (INTC) is experiencing a significant sentiment boost following two major capital-related developments. A $2 billion stock purchase by SoftBank and active discussions for the U.S. government to take a 10% equity stake, potentially injecting $10 billion by converting CHIPS Act grants, provide substantial financial support for its turnaround strategy under CEO Lip-Bu Tan. Despite this validation and de-risking of its balance sheet, analyst commentary indicates that underlying questions about the company's long-term competitive prospects persist. In the biotech sector, Viking Therapeutics (VKTX) faced a severe setback as its experimental oral obesity pill's mid-stage study revealed a high 28% patient dropout rate due to side effects, significantly diminishing its perceived ability to compete with market-leading injectable treatments from Eli Lilly and Novo Nordisk. Conversely, Home Depot (HD) showed signs of a potential market bottoming, with shares rising after reporting a return to growth. Its 1% increase in second-quarter comparable sales, while slightly below estimates, marks a material improvement from the 3.3% slump a year prior and suggests the downturn in the home improvement sector may be concluding.

Key Decisions for Investors

• For Intel, the significant capital injections from SoftBank and a potential US government stake de-risk the balance sheet for its turnaround, however, investors should remain focused on execution and tangible improvements in chip manufacturing before adding to positions.
• The high patient dropout rate in Viking Therapeutics' oral obesity drug trial represents a major clinical setback, warranting a fundamental re-evaluation of the asset's commercial viability and its ability to compete with established treatments.
• Home Depot's return to positive comparable sales growth suggests the home improvement sector may be stabilizing, and investors could view this as an early indicator of recovery, justifying a closer look at the stock as a cyclical play.